在动脉样硬化中用于内新血管化的药理学干预措施
Azizah Ugusman1, Nur Syahidah Nor Hisam2, Nur Syakirah Othman1
1Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia.
Pharmacology & therapeutics
|July 8, 2024
概括
针对内斑块新血管化的研究表明,它有望稳定动脉样硬化斑块. 这一系统性审查强调了临床前药理干预措施,这些干预措施有效地抑制了这一过程,可能降低了心脏病发作风险.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 动脉样硬化病理生理病理学
背景情况:
- 晚期动脉样硬化症的特点是斑块不稳定,增加心脏病发作风险.
- 内斑内新血管化是导致斑块不稳定和出血的关键因素.
- 药理上抑制斑块内新血管化的治疗策略尚未得到充分研究.
研究的目的:
- 系统地审查临床前药理学干预措施,以向板内新血管化.
- 评估新兴和当前的治疗方法,以抑制动脉样硬化中的内新血管化.
- 为增强斑块稳定性的潜在治疗方法提供见解.
主要方法:
- 从2013年1月到2024年2月,对电子数据库 (Web of Science,PubMed,Scopus,Ovid) 进行系统的文献搜索.
- 包括临床前研究 (体内和体外) 调查药理抑制内新血管化的研究.
- 分析报告有关诸如阿克西替尼,他类药物和氨酸等干预措施的研究.
主要成果:
- 十项临床前研究符合纳入标准,使用了各种动脉样硬化的动物模型.
- 评估了多种药理学药物,包括阿克西替尼,格林,K5,罗斯瓦斯塔丁,阿托瓦斯塔丁,3PO,埃弗罗利斯,黑激素,Si-Miao-Yong-A和原卡特丘伊克化物.
- 所有研究的干预措施都显示出通过各种信号通路抑制斑块内新血管化的有效性.
结论:
- 药理上抑制内新血管化是一种可行的策略,可以改善动脉样硬化斑块的稳定性.
- 临床前发现表明,有几条有前途的治疗途径可以缓解心血管事件.
- 对这些干预措施的进一步研究可能会导致高级动脉样硬化症的新治疗方法.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:27Open Angle Glaucoma: Treatment
427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:23Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502